News

Parkinson's and multiple sclerosis: Regensburg-based Lifespin continues research with 2.5 million euros

Regensburg-based Biopark Lifespin GmbH has successfully closed a €2.5 million bridge financing. The diagnostic data company is working on an AI-based health platform that can measure key metabolic parameters in patients and plans to raise Series A funding in 2022.

Founded in 2017 at the BioPark, Lifespin is one of the so-called "deep data companies" and is developing its own AI-based health testing platform to measure quantitative metabolic data in patient samples. An interdisciplinary team of currently 17 employees combines diagnostic and bioanalytical methods with software solutions, in particular the use of artificial intelligence (AI).

Metabolic profiles of over 130,000 patients make early diagnosis possible

Lifespin has now built a database - based on analysis by magnetic resonance technology - of metabolic profiles from more than 130,000 patients, enabling analysis of more than one billion metabolic relationships. Through systematic mapping, human metabolic health can be standardized. If significant differences in the metabolite profile are detectable, diseases can be diagnosed at an early stage and individual monitoring during the course of a therapy can be made possible.

The company sees its health diagnostics software applicable in the broader healthcare sector, from diagnostics to patient stratification to personalized medicine, as well as to support the drug discovery process.

"We are very excited about Lifespin's growth with a platform solution that can be accessed by collaborating clinical laboratories and drug discovery partners and scaled globally through our cloud solutions," said Dr. Ali Tinazli, CEO of Lifespin.

Focusing on multiple sclerosis and Parkinson's disease

Lifespin will use the bridge funding to advance the development of its first diagnostic panel for neurological diseases such as multiple sclerosis and Parkinson's disease, some of which cannot be diagnosed using traditional laboratory-based methods. The first commercial test of the differential diagnostic panel will cover early stages of multiple sclerosis. In addition, the panel will be expanded to include other neurological indications.

"Lifespin's new software-based approach to digitally capture, compare and analyze human metabolomes will open a new and exciting field that complements existing health diagnostics," said Robert Wieland, managing director of Wieland Capital, based in Munich, Germany, and Lifespin's lead investor.

In 2022, Lifespin plans to begin fundraising for a Series A to fund initial product launches and support the expansion of its operations into the United States.


Newsletter

Subscribe

Archive